Comparing Humoral Response and Safety after Third Dose of SARS-CoV-2 Vaccines in Healthcare Workers Who Received 2 Doses of CoronaVac

Main Article Content

Pongsathorn Gojaseni
Kanyika Wanvimonsuk
Saowanee Thianthong

Abstract

Background: Inactivated SARS-CoV-2 vaccines manufactured by Sinovac Life Sciences (CoronaVac) has been widely used in Thai healthcare workers. However, the emergence of delta variance raises the concern of immunity induced by CoronaVac. Therefore, a third dose booster using viral vector or mRNA vaccine has been recommended in frontline healthcare workers who received 2 doses of CoronaVac. This study aims to compare the level of anti-spike protein response and safety after third dose boosters in medical personnel of Royal Thai Air Force Hospital (SIKAN).


Methods: Immunoglobulin class G (IgG) against SARS-CoV-2 spike protein were measured before and 4 weeks after booster dose in medical personnel who volunteered to take part in this study.


Results: A total of 131 medical personnel who received booster doses of vaccine were included into this study (57 with viral vector vaccine, AstraZeneca and 74 with mRNA vaccine, Pfizer-BioNTech). There were no group differences regarding baseline characteristics, except for age that participants who received mRNA vaccine were significant younger. The anti-spike IgG antibody levels were significant increased in both groups, which the mRNA vaccinated group had increased more than the viral vector group (22,663 ± 10,999.5 vs. 9,900.5 ± 10,788.9 AU/ml, p < 0.001). Adverse events following immunization (AEFI) were found to be similar in both groups without any severe symptoms.


Conclusion: In healthcare professionals who had received two doses of CoronaVac, 3rd dose booster from both viral-vector and mRNA vaccines were effective, with the mRNA vaccine providing higher levels of immunity. The adverse events reported were mild to moderate.

Article Details

Section
Original Articles

References

กรมควบคุมโรค. รายงาน COVID-19 ประจำวัน ข้อมูลประจำประเทศไทย. 24 กรกฎาคม 2564.

[Available from: https://ddc.moph.go.th/viralpneumonia/situation.php]

WHO. Coronavirus disease (COVID-19): Vaccines. 2020.

[Available from: https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-vaccines]

กรมควบคุมโรค แนวทางการให้วัคซีนโควิด 19 ในสถานการณ์การระบาด ปี 2564 ของประเทศไทย ฉบับปรับปรุง ครั้งที่ 2 สิงหาคม 2564

[Available from: https://ddc.moph.go.th/vaccine-covid19/getFiles/11/1628849610213.pdf]

Tanriover MD, Doğanay HL, Akova M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac):

interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet 2021;398:213-22.

Jara A, Undurraga EA, González C, et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. N Engl J Med. 2021;385(10):875-

Poovorawan Y. Unpublished data [Available from: https://www.facebook.com/photo?

fbid=6018865244822709&set=a.192552250787400]

Immunoassay for the quantitative determination of antibodies to the SARS-CoV-2 spike protein [Available from:

https://diagnostics.roche.com/global/en/products/params/elecsys-anti-sars-cov-2-s.html.]

ศูนย์วิจัยคลินิก คณะแพทยศาสตร์ศิริราชพยาบาล รายงานผลการวิจัยเบื้องต้นในการศึกษาความปลอดภัยและการตอบสนองทางภูมิคุ้มกันจากการฉีดวัคซีน

กระตุ้นเข็ม 3 ในผู้ที่ได้รับวัคซีนซิโนแวคครบสองเข็ม [Available from: https://sicres.org/2021/09/13/covid19-vaccine-booster/]